TheJobsMapAbout Dogwood Therapeutics
Dogwood is pioneering Halneuron®, a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer pain, and other pain indications. It is also developing the antiviral combination therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”)
- Employees
- 11 to 50
Leadership
The top of Dogwood Therapeutics's org chart, with how many people report into each leader.
GD
Greg Duncan
Chief Executive Officer and Chairman
1 report
AW
Angela Walsh
Senior Vice President Of Finance
Jobs at Dogwood Therapeutics
No open positions right now. Explore more companies on TheJobsMap.